The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Through the use of carbon footprint and life cycle assessment (LCA) tools, essential data and information for biopharmaceutical manufacturing operations are obtained that can inform key decisions for product, process, and plant design. Discussion on the scope boundaries and the primary drivers that impact the assessments will be discussed.
Speaker(s):
Phillip
R. Smith,
PhD,
Director, Process Technology,
GlaxoSmithKline
Credits
Credits: None available.
You must be logged in and own this session in order to
post comments.
